The interrelation of needs and quality of life in

Authors: Karin Landolt Wulf Rössler Tom Burns Vladeta AjdacicGross Silvana Galderisi Jan Libiger Dieter Naber Eske M Derks René S Kahn W Wolfgang Fleischhacker

Publish Date: 2011/11/24

Volume: 262, Issue: 3, Pages: 207-216

PDF Link

Abstract

The interrelation between needs for care and quality of life has been described and replicated by several studies The present work aims to add to the understanding of longitudinal interrelations between needs for care quality of life and other outcome measures by analyzing a sample of patients at the onset of schizophrenia This study relied on data from the EUFEST trial designed to compare first and secondgeneration antipsychotics during 1 year At baseline 498 patients have been included The first baseline and the last assessment 12 months after baseline were used for the analyses Predictors of quality of life were determined using regression analyses We tested the complex longitudinal interrelations between baseline and outcome measures with structural equation models Unmet needs were not definitively confirmed as a predictor of subsequent quality of life unless unmet needs changing to no needs were separated from unmet needs changing to met needs Each unmet need that changed to no need enhanced the quality of life mean score 1–7 by 0136 scale points This study suggests that when studying quality of life and needs for treatment it is crucial to differentiate whether unmet needs disappeared or whether they were met as the former has a stronger impact on quality of lifeThe analyses presented in this paper were done without funding The EUFEST trial was funded by the European Group for Research in Schizophrenia EGRIS with grants from AstraZeneca Pfizer and SanofiAventis We thank all the patients who took part in the studyRSK has received grants honoraria for education programmes or served as consultant for Astellas AstraZeneca BMS Eli Lilly JanssenCilag Pfizer Roche and SanofiAventis WWF has received research grants from BMS/Otsuka Eli Lilly JanssenCilag and Servier honoraria for educational programmes from AstraZeneca and Pfizer speaking fees from AstraZeneca BMS/Otsuka JanssenCilag and Pfizer and advisory board honoraria from AstraZeneca BMS/Otsuka JanssenCilag Servier and Wyeth SG received fees for educational programmes or advisory boards from AstraZeneca InnovaPharma BristolMyers Squibb and JanssenCilag JL is a faculty member of Lundbeck Institute Lundbeck Neuroscience Foundation and received speaker’s fees travel grants or consultancy fees from Eli Lilly BristolMyers Squibb Lundbeck and Servier WR received speaker’s honoraria and served as a consultant for Elli Lilly JanssenCilag AstraZeneca and BMS TB DN EMD VAG and KL declare that they have no conflict of interestSteering Committee R S Kahn Utrecht The Netherlands W W Fleischhacker Innsbruck Austria H Boter Utrecht The Netherlands I P M Keet Amsterdam The Netherlands C Brugman Utrecht The Netherlands M Davidson Tel Hashomer Israel S Dollfus Caen France W Gaebel Düsseldorf Germany S Galderisi Naples Italy M Gheorghe Bucharest Romania I Gonen Bucharest Romania D E Grobbee Utrecht The Netherlands L G Hranov Sofia Bulgaria M Hummer Innsbruck Austria J Libiger Hradec Králové Czech Republic N Lindefors Stockholm Sweden J J LópezIbor Madrid Spain K Nijssen Utrecht The Netherlands J Peuskens Leuven Belgium A RiecherRössler Basel Switzerland J K Rybakowski Poznan Poland G Sedvall Stockholm Sweden M v Wilmsdorff Düsseldorf Germany

Keywords: